Comments on the article "effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations" by Marfella et al.: (Journal of Diabetes and Its Complications 24 [2010] 79-83)

Journal of Diabetes and its Complications

Volumn 25, Issue 5, 2011, Pages 352-353

  Avogaro, Angelo ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SITAGLIPTIN; VILDAGLIPTIN;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LETTER; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADAMANTANE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; MALE; NITRILES; PYRAZINES; PYRROLIDINES; TRIAZOLES;

EID: 80052769361     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2010.12.001     Document Type: Letter

References (18)

1. Alba M., Sheng D., Guan Y., Williams-Herman D., Larson P., Sachs J.R., Thornberry R., Herman G., Kaufman K.D., and Goldstein B.J. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement CMRO 25 2009 2507 2514
2. Balkau B., Shipley M., Jarrett R.J., Pyorala K., Pyorala M., Forhan A., and Eschwege E. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study Diabetes Care 21 1998 360 367 (Pubitemid 28101069)
3. Barr E.L., Zimmet P.Z., Welborn T.A., Jolley D., Magliano D.J., Dunstan D.W., Cameron A.J., Dwyer T., Taylor H.R., Tonkin A.M., Wong T.Y., McNeil J., and Shaw J.E. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) Circulation 116 2007 151 157 (Pubitemid 47057520)
4. Bergman A., Ebel D., Liu F., Stone J., Wang A., Zeng W., Chen L., Dilzer S., Lasseter K., Herman G., Wagner J., and Krishna R. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers Biopharmaceutics and Drug Disposition 28 2007 315 322 (Pubitemid 47439637)
5. Brownlee M., and Hirsch I.B. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications JAMA 295 2006 1707 1708
6. Ceriello A. Mechanisms of tissue damage in the postprandial state International Journal of Clinical Practice Supplement 2001 7 12
7. Ceriello A., Hanefeld M., Leiter L., Monnier L., Moses A., Owens D., Tajima N., and Tuomilehto J. Postprandial glucose regulation and diabetic complications Archives of Internal Medicine 164 2004 2090 2095 (Pubitemid 39410797)
8. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration? Diabetologia 52 2009 1219 1226
9. Esposito K., Ciotola M., Carleo D., Schisano B., Sardelli L., Di Tommaso D., Misso L., Saccomanno F., Ceriello A., and Giugliano D. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes Journal of Clinical Endocrinology and Metabolism 93 2008 1345 1350 (Pubitemid 351519731)
10. Haffner S.M. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease Endocrine Reviews 19 1998 583 592 (Pubitemid 28467712)
11. Kilpatrick E.S., Rigby A.S., and Atkin S.L. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes Diabetes Care 32 2009 1901 1903
12. Lachin J.M., Genuth S., Nathan D.M., Zinman B., and Rutledge B.N. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trials revisited Diabetes 57 2008 995 1001
13. Lindgren O., Mari A., Deacon C.F., Carr R.D., Winzell M.S., Vikman J., and Ahren B. Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men Journal of Clinical Endocrinology and Metabolism 94 2009 2887 2892
14. Mari A., Sallas W.M., He Y.L., Watson C., Ligueros-Saylan M., Dunning B.E., Deacon C.F., Holst J.J., and Foley J.E. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes Journal of Clinical Endocrinology and Metabolism 90 2005 4888 4894 (Pubitemid 41159387)
15. Pankow J.S., Kwan D.K., Duncan B.B., Schmidt M.I., Couper D.J., Golden S., and Ballantyne C.M. Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study Diabetes Care 30 2007 325 331 (Pubitemid 46198338)
16. Service F.J., Molnar G.D., Rosevear J.W., Ackerman E., Gatewood L.C., and Taylor W.F. Mean amplitude of glycemic excursions, a measure of diabetic instability Diabetes 19 1970 644 655
17. Vilsboll T., Krarup T., Sonne J., Madsbad S., Volund A., Juul A.G., and Holst J.J. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus Journal of Clinical Endocrinology and Metabolism 88 2003 2706 2713 (Pubitemid 36724446)
18. Vincent S.H., Reed J.R., Bergman A.J., Elmore C.S., Zhu B., Xu S., Ebel D., Larson P., Zeng W., Chen L., Dilzer S., Lasseter K., Gottesdiener K., Wagner J.A., and Herman G.A. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans Drug Metabolism and Disposition 35 2007 533 538 (Pubitemid 46513255)